Muluneh B - Search Results

1

Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.

Cole AL, Wood WA Jr, Muluneh B, Lund JL, Elston Lafata J, Dusetzina SB. Cole AL, et al. Among authors: muluneh b. JCO Oncol Pract. 2020 May;16(5):e443-e455. doi: 10.1200/JOP.19.00301. Epub 2020 Mar 20. JCO Oncol Pract. 2020. PMID: 32196424

2

Obstacles to affordable cancer treatments.

Dusetzina SB, Muluneh B, Khan T, Richards KL, Keating NL. Dusetzina SB, et al. Among authors: muluneh b. N C Med J. 2014 Jul-Aug;75(4):257-60. doi: 10.18043/ncm.75.4.257. N C Med J. 2014. PMID: 25046090 Free article.

3

Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults.

Dusetzina SB, Muluneh B, Keating NL, Huskamp HA. Dusetzina SB, et al. Among authors: muluneh b. N Engl J Med. 2020 Dec 10;383(24):2299-2301. doi: 10.1056/NEJMp2027580. Epub 2020 Dec 5. N Engl J Med. 2020. PMID: 33283988 No abstract available.

4

Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.

Szeto AH, Bucci T, Deal A, Zhu A, Ahmad M, Cass AS, Sketch MR, Kemper R, Zeidner JF, Foster MC, Muluneh B, Crona DJ. Szeto AH, et al. Among authors: muluneh b. Ann Pharmacother. 2022 Jul;56(7):753-763. doi: 10.1177/10600280211044160. Epub 2021 Sep 18. Ann Pharmacother. 2022. PMID: 34541881 Free article.

5

Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review.

Elston Lafata J, Nguyen B, Staresinic C, Johnson M, Gratie D, Muluneh B. Elston Lafata J, et al. Among authors: muluneh b. J Oncol Pharm Pract. 2023 Mar;29(2):358-369. doi: 10.1177/10781552211073576. Epub 2022 Jan 20. J Oncol Pharm Pract. 2023. PMID: 35048768

6

Oral oncolytic treatment for chronic lymphocytic leukemia.

Harris V, Borlagdan J, Muluneh B. Harris V, et al. Among authors: muluneh b. J Oncol Pharm Pract. 2022 Jun;28(4):935-944. doi: 10.1177/10781552211073906. Epub 2022 Jan 27. J Oncol Pharm Pract. 2022. PMID: 35084245 Review.

7

Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.

Collins J 4th, Stump SE, Heiling H, Muir M, Deal A, Proco D, Nguyen C, Cozad M, Mato A, Coombs CC, Muluneh B. Collins J 4th, et al. Among authors: muluneh b. Leuk Lymphoma. 2022 Aug;63(8):1823-1830. doi: 10.1080/10428194.2022.2045597. Epub 2022 Mar 6. Leuk Lymphoma. 2022. PMID: 35249442

8

Barriers and facilitators associated with implementing interventions to support oral anticancer agent adherence in academic and community cancer center settings.

Muluneh B, Muir MA, Collins JB, Proco D, Mackler E, Leak Bryant A, Wood WA, Tilkens M, Reichard JS, Foster M, Gatwood J, Wheeler SB, Zullig LL, Elston Lafata J. Muluneh B, et al. PLoS One. 2023 Jul 21;18(7):e0286630. doi: 10.1371/journal.pone.0286630. eCollection 2023. PLoS One. 2023. PMID: 37478078 Free PMC article.

9

Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia.

Collins JB, Muluneh B, Profitt S. Collins JB, et al. Among authors: muluneh b. J Oncol Pharm Pract. 2024 Mar;30(2):385-396. doi: 10.1177/10781552231217694. Epub 2023 Dec 17. J Oncol Pharm Pract. 2024. PMID: 38105466 Free PMC article. Review.

10

Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.

Muluneh B, Deal A, Alexander MD, Keisler MD, Markey JM, Neal JM, Bernard S, Valgus J, Dressler LG. Muluneh B, et al. J Oncol Pharm Pract. 2018 Mar;24(2):98-109. doi: 10.1177/1078155216679026. Epub 2016 Nov 30. J Oncol Pharm Pract. 2018. PMID: 27895220

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

60 results

Search Page